LivaNova (LIVN)
(Delayed Data from NSDQ)
$51.43 USD
-0.99 (-1.89%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $51.57 +0.14 (0.27%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LIVN 51.43 -0.99(-1.89%)
Will LIVN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LIVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LIVN
LivaNova (LIVN) Q1 Earnings and Revenues Top Estimates
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline
LIVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
LivaNova (LIVN) Earnings Expected to Grow: Should You Buy?
LivaNova (LIVN) Soars 12.5%: Is Further Upside Left in the Stock?
LivaNova (LIVN) Q4 Earnings and Revenues Top Estimates
Other News for LIVN
LivaNova to Announce Second-Quarter 2024 Results
Jefferies medical technology analyst holds analyst/industry conference call
LivaNova’s Annual Meeting Strengthens Shareholder Alignment
LivaNova: A Strong Buy Opportunity Amidst RECOVER Trial Developments
Analysts Are Bullish on These Healthcare Stocks: LivaNova (LIVN), BridgeBio Pharma (BBIO)